Surface-modified liposomal in-situ nasal gel enhances brain targeting of berberine hydrochloride for Alzheimer’s therapy: optimization and in vivo studies

gel significantly decreased escape latency and path length in comparison to the control group. Histopathological assessment showed that the formulated gel was safe for intranasal administration. The developed formulation has the potential to effectively enhance the efficacy of BER in Alzheimer's disease management.